Market
Shift in hydroxychloroquine guidelines by major health organizations by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Statements or guidelines from WHO, CDC, or other major health organizations
Story
Didier Raoult's IHU Hydroxychloroquine Study Officially Retraction After Five-Year COVID-19 Controversy
Dec 17, 2024, 01:00 PM
The prominent study on hydroxychloroquine for COVID-19, led by Professor Didier Raoult and his team at the IHU Méditerranée Infection in Marseille, has been officially retracted. This research had been a cornerstone for proponents of the drug as a treatment against COVID-19. The retraction marks a significant development in the ongoing debate over the efficacy of hydroxychloroquine, which has faced scrutiny regarding its methodology and conclusions. The study, which had been defended by Raoult and his colleague Philippe Gautret, has been invalidated after nearly five years of controversy surrounding its claims. Critics have long argued that the study should have been retracted much earlier, reflecting the contentious nature of hydroxychloroquine's role in the pandemic response.
View original story
Similar markets
No • 50%
Yes • 50%
Oppose changes • 25%
Support changes • 25%
No official stance • 25%
Neutral stance • 25%
No • 50%
Yes • 50%
European Medicines Agency • 25%
CDC • 25%
Other • 25%
WHO • 25%
Supportive • 25%
Neutral • 25%
Critical • 25%
No significant response • 25%
Yes • 50%
No • 50%
No official response • 25%
Dismiss the findings • 25%
Issue new warnings • 25%
Conduct further studies • 25%
Other changes • 25%
Looser vaccine mandates • 25%
Stricter vaccine mandates • 25%
No change • 25%
Support • 25%
Neutral • 25%
No Statement • 25%
Oppose • 25%